Table 3.
List of CF transmembrane conductance regulator (CFTR) mutations eligible for the treatment with Kalydeco® and Symdeko®/Symkevi®.
| Kalydeco® | |||
| E56K | P67L | R74W | |
| D110E | D110H | R117C | |
| R117H | G178R | E193K | |
| L206W | R347H | R352Q | |
| A455E | S549N | S549R | |
| G551D | G551S | D579G | |
| 711+3A>G | E831X | S945L | |
| S977F | F1052V | K1060T | |
| A1067T | G1069R | R1070Q | |
| R1070W | F1074L | D1152H | |
| G1244E | S1251N | S1255P | |
| D1270N | G1349D | 2789+5G>A | |
| 3272-26A>G | 3849+10kbC>T | ||
| Symdeko® or Symkevi® (‡) | |||
| F508del | P67L | D110H | |
| R117C | L206W | R347H | |
| R352Q | A455E | D570G | |
| 711+3A>G | E831X | S945L | |
| S977F | R1070W | D1152H | |
| 2789+5G>A | 3272-26A>G | 3849+10kbC>T | |
(‡) Patients should carry at least one F508del mutation.